Roivant Sciences (ROIV) leader exercises options and sells 200K shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. officer Eric Venker, President & Immunovant CEO, reported equity transactions dated December 9, 2025. He exercised stock options to acquire 200,000 common shares at an exercise price of $3.85 per share, then sold 200,000 common shares at a weighted average price of $20.85 per share pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

After these transactions, he directly beneficially owned 1,497,908 common shares of Roivant Sciences. He also held 5,876,523 stock options exercisable into common stock at $3.85 per share, from a grant with a vesting commencement date of April 20, 2022 that vests 25% on the first anniversary and the remainder in 36 equal monthly installments, with an expiration date of April 19, 2032.

Insider Trade Summary

Net Seller: 200,000 shares ($4,170,000)

Net Sell 3 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 200,000 shs ($4.17M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	200,000	$0.00	--
Exercise	Common Shares	200,000	$3.85	$770K
Sale	Common Shares	200,000	$20.85	$4.17M

Holdings After Transaction: Stock Option (Right to Buy) — 5,876,523 shares (Direct); Common Shares — 1,697,908 shares (Direct)

Footnotes (1)

1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	12/09/2025		M		200,000	A	$3.85	1,697,908	D
Common Shares	12/09/2025		S		200,000	D	$20.85(1)	1,497,908	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	12/09/2025		M			200,000	(2)	04/19/2032	Common Stock	200,000	$0	5,876,523	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Roivant Sciences (ROIV) report in this filing?

The filing reports that officer Eric Venker, President & Immunovant CEO, exercised stock options for 200,000 common shares and sold 200,000 common shares of Roivant Sciences Ltd. on December 9, 2025.

At what prices did the Roivant Sciences insider exercise options and sell shares?

He exercised stock options at an exercise price of $3.85 per share and sold 200,000 common shares at a weighted average price of $20.85 per share, as disclosed in the transaction table.

How many Roivant Sciences (ROIV) shares does the insider own after these transactions?

Following the reported option exercise and share sale, Eric Venker beneficially owned 1,497,908 common shares of Roivant Sciences Ltd. directly.

What stock options does the Roivant Sciences insider still hold after the transaction?

After the transactions, he held 5,876,523 stock options exercisable into Roivant common stock at an exercise price of $3.85 per share, with an expiration date of April 19, 2032.

Was the Roivant Sciences share sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the common share sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025, and the reported sale price is a weighted average.

When did the reported Roivant Sciences option grant start vesting and how does it vest?

The reported stock option award has a vesting commencement date of April 20, 2022. It vests and becomes exercisable 25% on the first anniversary of that date and then in 36 equal monthly installments thereafter, subject to continued service under the award terms.